A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Verastem, Inc.
Servier
Pfizer
Eli Lilly and Company
Hummingbird Bioscience
Novartis
Bristol-Myers Squibb
Merck Sharp & Dohme LLC
Fate Therapeutics
Alterome Therapeutics, Inc.
Novartis
Revolution Medicines, Inc.
Pfizer
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
BeOne Medicines
AstraZeneca
Incyte Corporation
Pfizer
Tizona Therapeutics, Inc
Genentech, Inc.
SWOG Cancer Research Network
Revolution Medicines, Inc.
Jacobio Pharmaceuticals Co., Ltd.
Memorial Sloan Kettering Cancer Center
PAQ Therapeutics, Inc.
Bristol-Myers Squibb
Bristol-Myers Squibb
Genentech, Inc.
Eli Lilly and Company
Genfleet Therapeutics (Shanghai) Inc.
Bristol-Myers Squibb